Hengrui Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hengrui Sun has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Beth A. Davison
Momentum Research , Durham, NC
1 shared publication - Gad Cotter
Momentum Research , Durham, NC
1 shared publication Gary G. Koch
From the Momentum Research Inc., Durham, NC (H.S., B.A.D., G.C.); Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC (H.S., G.G.K.); and Harvard Clinical Research Institute, Boston, MA (M.J.P.).
1 shared publicationMichael J. Pencina
From the Momentum Research Inc., Durham, NC (H.S., B.A.D., G.C.); Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC (H.S., G.G.K.); and Harvard Clinical Research Institute, Boston, MA (M.J.P.).
1 shared publication
Latest Publications
- 1 November 2012
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 5 (6) , 742-749
Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials
Background—: To assess concomitant simultaneous effects on multiple end points using global statistical methods in phase II acute heart failure studies. Methods and Results—: Using simulations we have assessed different statistical methods to evaluate concomitant effects of a new intervention on dyspnea relief (using 2 measures), length of hospital stay, worsening heart failure to 5 days, mortality, and heart failure readmission to 30 days. Treatment effect scenarios included large (20% to 28% relative improvements) and very large (30% to 43% relative improvements) effects among others. Placebo responses and correlations among end points typical in recent acute heart failure clinical trials were used. Powers for the average Z score exceeded 70% with ≥75 patients per group for 35% relative improvement across all 6 end points. Assessing dyspnea alone generally provides lower power than the average Z score approach, with power deducted ≈50% under most of scenarios. Other approaches generally provide lower power than the average Z score method. Conclusions—: Assessing the effects of new therapies on multiple clinical end points using the average Z score enables detection of therapeutic efficacy using sample sizes of 100 to 150 patients per group, approximately double the power achievable assessing the effects on dyspnea alone.
- 1 November 2012
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 5 (6) , 742-749
Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials
Background—: To assess concomitant simultaneous effects on multiple end points using global statistical methods in phase II acute heart failure studies. Methods and Results—: Using simulations we have assessed different statistical methods to evaluate concomitant effects of a new intervention on dyspnea relief (using 2 measures), length of hospital stay, worsening heart failure to 5 days, mortality, and heart failure readmission to 30 days. Treatment effect scenarios included large (20% to 28% relative improvements) and very large (30% to 43% relative improvements) effects among others. Placebo responses and correlations among end points typical in recent acute heart failure clinical trials were used. Powers for the average Z score exceeded 70% with ≥75 patients per group for 35% relative improvement across all 6 end points. Assessing dyspnea alone generally provides lower power than the average Z score approach, with power deducted ≈50% under most of scenarios. Other approaches generally provide lower power than the average Z score method. Conclusions—: Assessing the effects of new therapies on multiple clinical end points using the average Z score enables detection of therapeutic efficacy using sample sizes of 100 to 150 patients per group, approximately double the power achievable assessing the effects on dyspnea alone.